“Pioneering” p53 Reactivator Shows Proof-of-Concept in Phase I Trial
Abstract
Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.
Fields of Study & Subjects
Cancer-related Molecular Pathways
Cell death mechanisms and regulation
PI3K/AKT/mTOR signaling in cancer
Publication details
- Journal / source
- Cancer Discovery
- Volume
- 16
- Issue
- 4
- Pages
- OF1–OF1
- Publication date
- 27 February 2026
- Language
- EN